Tag Archives: BMY

Ziopharm’s Pause On Its Phase 3 Brain Cancer Study Is More Valuable Than You Think

Recently, Ziopharm Oncology (NASDAQ:ZIOP) gave an update on its first-quarter 2018 earnings report. It noted that a phase 3 study would be paused for the time being. The biotech is now pointing to its other mid-stage studies as being more prominent than the phase 3 study that was supposed to start soon treating patients with recurrent glioblastoma (brain cancer). I have to agree with this assessment,....More>>>

Ziopharm’s Pause On Its Phase 3 Brain Cancer Study Is More Valuable Than You Think

Recently, Ziopharm Oncology (NASDAQ:ZIOP) gave an update on its first-quarter 2018 earnings report. It noted that a phase 3 study would be paused for the time being. The biotech is now pointing to its other mid-stage studies as being more prominent than the phase 3 study that was supposed to start soon treating patients with recurrent glioblastoma (brain cancer). I have to agree with this assessment,....More>>>

Is Agenus Inc. (AGEN) a Buy?

Harnessing the power of the immune system to fight cancer is a big deal and Agenus Inc. (NASDAQ:AGEN) looks like a great way to follow the trend. This stock trades like a small-cap biotech, but a couple of candidates coming through its pipeline could help push annual revenue past the $1 billion mark. Plus, by this time next year, the company could have half a dozen or so new candidates in clinical....More>>>

Shepherd Financial Partners LLC Trims Position in Bristol-Myers Squibb (BMY)

Shepherd Financial Partners LLC reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 3.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,720 shares of the biopharmaceutical company’s stock after selling 1,380 shares during the quarter. Bristol-Myers Squibb makes up 0.7% of Shepherd Financial....More>>>

Shepherd Financial Partners LLC Trims Position in Bristol-Myers Squibb (BMY)

Shepherd Financial Partners LLC reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 3.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,720 shares of the biopharmaceutical company’s stock after selling 1,380 shares during the quarter. Bristol-Myers Squibb makes up 0.7% of Shepherd Financial....More>>>

Week In Review: Nearly $2 Billion Late-December Week For China Pharma Deals

Nanjing Legend Biotech received a $350 million upfront payment from Janssen Biotech, which will form a global partnership with Legend for its highly effective CAR-T candidate. In June, Legend, which was not previously well known, surprised the annual ASCO meeting with stunningly positive results from an early trial of the CAR-T molecule in patients with multiple myeloma. In addition to the $350....More>>>

10 Biotech Stocks With Game-Changing Dates in Q3

For some investors, they’ve created small fortunes. For others, they’ve brought nothing but misery. For all investors, though, there’s no denying the fact that biotech stocks have kept things interesting if only because they can always supply a binary even traders can treat like a coin toss. The third quarter of 2017 isn’t going to be any different.

To....More>>>

Should You Buy Gilead Sciences, Inc (GILD) Stock Ahead Of Q4 Earnings?


Flickr

Shares of Foster City, California-based, biotech major, Gilead Sciences, Inc(NASDAQ:GILD) have been on a consistent decline in the last one year or so. After being one of the best performers in the biotech space since 2012, Gilead stock has lost more than 12% in last one year, while theNasdaq Composite (INDX:COMPX) has gained by more than 24% in the same period, resulting in....More>>>

Bristol-Myers Squibb: Much Ado About (Almost) Nothing

“Mors tua, vita mea” (literally “your death is my life) probably was the motto that gladiators, in the ancient Rome, recited before entering in the Coliseum and fighting for their life. Over and above its literal translation, this Latin expression means that what is a damage for one person is often an advantage for another. There can only be one winner in a competition;....More>>>

Bristol-Myers Squibb: There Goes Any Chance for Upside

Poor Bristol-Myers Squibb (BMY)–and poor anyone who had been bullish on its shares.

That would include Barron’s Jack Hough, who listed it as a stock on sale on Jan. 13. It’s even more on sale today, however, after Bristol-Myers said that it wouldn’t seek accelerated approval of its lung-cancer treatment combination last night, with shares off 10% at $49.94....More>>>